[S02DA03, antipyrine, The risk or severity of hyperkalemia can be increased when Antipyrine is combined with Methsuximide.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Methsuximide.]
[L04AA27, fingolimod, Methsuximide may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methsuximide.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Methsuximide.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hyperkalemia can be increased when Sulindac is combined with Methsuximide.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Methsuximide.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Methsuximide is combined with Sulthiame.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Azapropazone.]
[L01BB02, mercaptopurine, Methsuximide may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Methsuximide.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Methsuximide.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Methsuximide.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Methsuximide.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Methsuximide.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Methsuximide is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Methsuximide.]
[L04AX02, thalidomide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Methsuximide may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, Methsuximide may increase the excretion rate of Theophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Eribulin.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Methsuximide.]
[N05CA19, thiopental, The metabolism of Thiopental can be decreased when combined with Methsuximide.]
[N05AB08, thioproperazine, The risk or severity of hypotension can be increased when Thioproperazine is combined with Methsuximide.]
[N05AC02, thioridazine, The risk or severity of hypotension can be increased when Thioridazine is combined with Methsuximide.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Methsuximide.]
[C01BB04, aprindine, Aprindine may increase the arrhythmogenic activities of Methsuximide.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Methsuximide is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Methsuximide can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Methsuximide is combined with Timolol.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Tolazamide.]
[M02AX02, tolazoline, The risk or severity of hypotension can be increased when Tolazoline is combined with Methsuximide.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Methsuximide.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Methsuximide is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Methsuximide is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methsuximide.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Methsuximide.]
[C03DB02, triamterene, The risk or severity of hyperkalemia can be increased when Triamterene is combined with Methsuximide.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Methsuximide.]
[A03AB12, mepenzolate, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Methsuximide.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Methsuximide is combined with Trifluperidol.]
[N05AA05, triflupromazine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Methsuximide may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Methsuximide may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Methsuximide.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Methsuximide.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Methsuximide.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Methsuximide.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Methsuximide.]
[A03BB01, butylscopolamine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Methsuximide is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Methsuximide.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, Methsuximide may increase the neuromuscular blocking activities of Tubocurarine.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Vandetanib.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Methsuximide can be increased when it is combined with Boceprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Ezogabine is combined with Methsuximide.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Methsuximide.]
[C08DA01, verapamil, Verapamil may increase the arrhythmogenic activities of Methsuximide.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Viloxazine.]
[N05AF05, zuclopenthixol, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Methsuximide.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Methsuximide.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Methsuximide.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Methsuximide.]
[R03DC01, zafirlukast, The metabolism of Methsuximide can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Methsuximide can be decreased when combined with Rabeprazole.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Methsuximide.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Methsuximide.]
[N02BA01, aspirin, The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Methsuximide.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Methsuximide.]
[G04BD07, tolterodine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Methsuximide.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Methsuximide.]
[M03AC04, atracurium, Methsuximide may increase the neuromuscular blocking activities of Atracurium.]
[S01FA01, atropine, Atropine may increase the arrhythmogenic activities of Methsuximide.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Methsuximide.]
[J01CA09, azlocillin, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Azlocillin.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Methsuximide.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Mirabegron.]
[L02BB04, enzalutamide, The serum concentration of Methsuximide can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Methsuximide.]
[A02AA05, magnesium silicate, The risk or severity of hypotension can be increased when Magnesium silicate is combined with Methsuximide.]
[L01EX05, regorafenib, Methsuximide may increase the bradycardic activities of Regorafenib.]
[N05CA04, barbital, The metabolism of Methsuximide can be increased when combined with Barbital.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may increase the arrhythmogenic activities of Methsuximide.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Methsuximide.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Methsuximide.]
[C08CA13, lercanidipine, Lercanidipine may increase the arrhythmogenic activities of Methsuximide.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Methsuximide is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Methsuximide.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.]
[L04AA29, tofacitinib, Methsuximide may increase the bradycardic activities of Tofacitinib.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Methsuximide.]
[R06AC06, thonzylamine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Methsuximide is combined with Diethyl ether.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Methsuximide can be decreased when combined with Sildenafil.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Methsuximide.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Bedaquiline.]
[C04AX11, bencyclane, Methsuximide may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Alogliptin.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the bradycardic activities of Methsuximide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Methsuximide is combined with Benperidol.]
[A10BK02, canagliflozin, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Gemifloxacin.]
[M04AB03, benzbromarone, The metabolism of Methsuximide can be decreased when combined with Benzbromarone.]
[A12CC09, magnesium orotate, The risk or severity of hypotension can be increased when Magnesium orotate is combined with Methsuximide.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Moxifloxacin.]
[A06AX06, tegaserod, The therapeutic efficacy of Tegaserod can be decreased when used in combination with Methsuximide.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin detemir.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Benzocaine.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Pramlintide.]
[M01AH01, celecoxib, The risk or severity of hyperkalemia can be increased when Celecoxib is combined with Methsuximide.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Methsuximide.]
[A12CC05, magnesium aspartate, The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Methsuximide.]
[N04AC01, benztropine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Methsuximide can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Methsuximide is combined with Levomilnacipran.]
[C08EA02, bepridil, Bepridil may increase the arrhythmogenic activities of Methsuximide.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Lixisenatide.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Vortioxetine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Methsuximide.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Methsuximide can be increased when it is combined with Luliconazole.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Methsuximide.]
[A10BK01, dapagliflozin, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Dapagliflozin.]
[C07AB04, acebutolol, Acebutolol may increase the arrhythmogenic activities of Methsuximide.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Methsuximide is combined with Tasimelteon.]
[L04AA32, apremilast, The metabolism of Methsuximide can be increased when combined with Apremilast.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Methsuximide.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Methsuximide can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, Methsuximide may increase the bradycardic activities of Ceritinib.]
[A03BA03, hyoscyamine, Hyoscyamine may increase the arrhythmogenic activities of Methsuximide.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Methsuximide.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Methsuximide is combined with Alfaxalone.]
[A10BK03, empagliflozin, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Olodaterol.]
[D11AA01, glycopyrronium, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Methsuximide can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The risk or severity of hypotension can be increased when Acepromazine is combined with Methsuximide.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Methsuximide.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Dulaglutide.]
[N04AA02, biperiden, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Methsuximide.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Methsuximide.]
[N06AX11, mirtazapine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Methsuximide can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Panobinostat.]
[A03AA09, difemerine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[C01EB17, ivabradine, Methsuximide may increase the bradycardic activities of Ivabradine.]
[N05AX16, brexpiprazole, The risk or severity of hypotension can be increased when Brexpiprazole is combined with Methsuximide.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Flibanserin is combined with Methsuximide.]
[A06AD03, magnesium peroxide, The risk or severity of hypotension can be increased when Magnesium peroxide is combined with Methsuximide.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Cariprazine.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Methsuximide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin degludec.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Methsuximide.]
[A02BC03, lansoprazole, The metabolism of Methsuximide can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Methsuximide.]
[J02AC05, isavuconazole, The metabolism of Methsuximide can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Methsuximide.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Acetohexamide.]
[G04CA01, alfuzosin, The risk or severity of hypotension can be increased when Alfuzosin is combined with Methsuximide.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Methsuximide.]
[M01AE16, alminoprofen, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Methsuximide is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Methsuximide.]
[N04BC01, bromocriptine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Methsuximide.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Methsuximide.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methsuximide.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Amineptine is combined with Methsuximide.]
[C08CA01, amlodipine, Amlodipine may increase the arrhythmogenic activities of Methsuximide.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Methsuximide.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Bupivacaine.]
[C07AA19, bupranolol, Methsuximide may increase the arrhythmogenic activities of Bupranolol.]
[N07BC01, buprenorphine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Buserelin.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Methsuximide.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, Rivastigmine may increase the bradycardic activities of Methsuximide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Artemether.]
[M02AA03, clofezone, The metabolism of Methsuximide can be decreased when combined with Rabeprazole.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Methsuximide.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Methsuximide.]
[S01GX07, azelastine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Methsuximide can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Azithromycin.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Methsuximide.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hyperkalemia can be increased when Balsalazide is combined with Methsuximide.]
[R03DA08, bamifylline, Methsuximide may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Methsuximide can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Beclamide.]
[N06BC01, caffeine, Methsuximide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA07, benazepril, The risk or severity of hyperkalemia can be increased when Benazepril is combined with Methsuximide.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Benfluorex.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Oxybuprocaine.]
[G04BA03, calcium chloride, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium chloride.]
[J01XX08, linezolid, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Linezolid.]
[J05AE09, tipranavir, The metabolism of Methsuximide can be decreased when combined with Tipranavir.]
[D11AX03, calcium gluconate, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium gluconate.]
[L04AB02, infliximab, The metabolism of Methsuximide can be increased when combined with Infliximab.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Safinamide.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Delafloxacin.]
[D01AC10, bifonazole, The therapeutic efficacy of Bifonazole can be increased when used in combination with Methsuximide.]
[P03AC02, bioallethrin, Methsuximide may increase the arrhythmogenic activities of Bioallethrin.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Methsuximide.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Methsuximide.]
[C07AB07, bisoprolol, The therapeutic efficacy of Methsuximide can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The serum concentration of Methsuximide can be decreased when it is combined with Efavirenz.]
[C07AA17, bopindolol, The risk or severity of bradycardia can be increased when Methsuximide is combined with Bopindolol.]
[N04AA11, bornaprine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Methsuximide is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Methsuximide is combined with Brotizolam.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Canrenone.]
[M01AB07, bumadizone, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Methsuximide.]
[J05AX18, letermovir, The metabolism of Methsuximide can be increased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Methsuximide is combined with Butriptyline.]
[C01AA02, acetyldigoxins, Methsuximide may increase the arrhythmogenic activities of Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Semaglutide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Capsaicin.]
[A10BK04, ertugliflozin, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Ertugliflozin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Methsuximide is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Acrivastine.]
[C09AA01, captopril, The risk or severity of hyperkalemia can be increased when Captopril is combined with Methsuximide.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Methsuximide can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, Carbamazepine may increase the Change in thyroid function activities of Methsuximide.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Methsuximide.]
[A03AA03, camylofine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Methsuximide.]
[C07AG02, carvedilol, Carvedilol may increase the arrhythmogenic activities of Methsuximide.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Methsuximide.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Encorafenib.]
[C07AB08, celiprolol, Celiprolol may increase the arrhythmogenic activities of Methsuximide.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Methsuximide can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Methsuximide can be decreased when combined with Tecovirimat.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Methsuximide.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Methsuximide is combined with Carbromal.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Carbutamide.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Lornoxicam.]
[R03DA02, oxtriphylline, Methsuximide may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Inotersen.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Methsuximide.]
[R03BB08, revefenacin, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Methsuximide can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Amifampridine.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Methsuximide.]
[C01BG07, cifenline, Methsuximide may increase the arrhythmogenic activities of Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of hyperkalemia can be increased when Cilazapril is combined with Methsuximide.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Methsuximide.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Methsuximide is combined with Cinitapride.]
[S01ED05, carteolol, Methsuximide may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The metabolism of Methsuximide can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Esketamine.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation and hypotension can be increased when Clarithromycin is combined with Methsuximide.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Methsuximide is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Methsuximide is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Methsuximide.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Methsuximide.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Methsuximide.]
[V03AE07, calcium acetate, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium acetate.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Methsuximide can be increased when combined with Etanercept.]
[A12CC06, magnesium lactate, The risk or severity of hypotension can be increased when Magnesium lactate is combined with Methsuximide.]
[L01EM03, alpelisib, The metabolism of Methsuximide can be decreased when combined with Alpelisib.]
[J01DD01, cefotaxime, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Cefotaxime.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Cyamemazine.]
[C03BX03, cicletanine, Methsuximide may increase the arrhythmogenic activities of Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Methsuximide.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Methsuximide.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Entrectinib.]
[N07XX11, pitolisant, Methsuximide may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Methsuximide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Methsuximide.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin pork.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Methsuximide.]
[J01DB03, cephalothin, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Cefalotin.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Methsuximide.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Methsuximide.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Methsuximide.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Methsuximide.]
[N03AX25, cenobamate, The serum concentration of Methsuximide can be increased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methsuximide.]
[R06AB02, dexchlorpheniramine, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Methsuximide.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Methsuximide is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Methsuximide is combined with Lumateperone.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Methsuximide.]
[H02CA02, osilodrostat, The metabolism of Methsuximide can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Methsuximide can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Methsuximide.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Methsuximide.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Methsuximide.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Methsuximide.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Methsuximide.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methsuximide.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Methsuximide.]
[M01AH02, rofecoxib, The risk or severity of hyperkalemia can be increased when Rofecoxib is combined with Methsuximide.]
[C08CA16, clevidipine, Clevidipine may increase the arrhythmogenic activities of Methsuximide.]
[C01BD07, dronedarone, Dronedarone may increase the arrhythmogenic activities of Methsuximide.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Methsuximide.]
[L01AA02, chlorambucil, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Chlorambucil.]
[S03AA08, chloramphenicol, The metabolism of Methsuximide can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Chlorcyclizine.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methsuximide.]
[A03AA08, dihexyverine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[G04BD09, trospium, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Droxicam.]
[M02AA27, dexketoprofen, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Methsuximide is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Methsuximide.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Dyclonine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Methsuximide.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Methsuximide is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Methsuximide can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Methsuximide is combined with Oliceridine.]
[P01BA01, chloroquine, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Methsuximide.]
[N05AA01, chlorpromazine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Chlorpropamide.]
[N05AF03, chlorprothixene, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methsuximide.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Ethenzamide.]
[N06BX18, vinpocetine, Methsuximide may increase the arrhythmogenic activities of Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methsuximide.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Methsuximide.]
[M01AB08, etodolac, The risk or severity of hyperkalemia can be increased when Etodolac is combined with Methsuximide.]
[M02AA06, etofenamate, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Etofenamate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Methsuximide can be decreased when combined with Lonafarnib.]
[M09AA01, hydroquinine, Methsuximide may increase the arrhythmogenic activities of Hydroquinine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Relugolix.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Methsuximide is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Methsuximide.]
[M01AE05, fenbufen, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Fenbufen.]
[N06BA10, fenethylline, Methsuximide may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Flumequine.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Methsuximide.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Methsuximide.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Methsuximide is combined with Trichloroethylene.]
[A02BA01, cimetidine, The serum concentration of Methsuximide can be increased when it is combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Methsuximide.]
[N07CA02, cinnarizine, Cinnarizine may increase the arrhythmogenic activities of Methsuximide.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ciprofloxacin.]
[N06AB04, citalopram, Methsuximide may increase the QTc-prolonging activities of Citalopram.]
[H01AC07, somapacitan, The metabolism of Methsuximide can be decreased when combined with Somapacitan.]
[C03DA05, finerenone, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Finerenone.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Methsuximide is combined with Fexinidazole.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Methsuximide.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Clemastine.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Gliquidone.]
[A12AA02, calcium glubionate, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium glubionate anhydrous.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when St. John's Wort is combined with Methsuximide.]
[L01EA06, asciminib, The metabolism of Methsuximide can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Methsuximide.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Methsuximide.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Methsuximide.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Methsuximide can be decreased when combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Methsuximide.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Methsuximide.]
[C01EB24, mavacamten, The serum concentration of Methsuximide can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Tirzepatide.]
[J02AC06, oteseconazole, The therapeutic efficacy of Oteseconazole can be increased when used in combination with Methsuximide.]
[A02BC08, vonoprazan, The metabolism of Methsuximide can be decreased when combined with Vonoprazan.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Methsuximide.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Methsuximide.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Methsuximide.]
[N05AH02, clozapine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Sotagliflozin.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Methsuximide.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Cocaine.]
[C02KB01, metyrosine, Methsuximide may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Methsuximide can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Methsuximide.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Methsuximide.]
[A03AB10, hexocyclium, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[C01BA13, hydroquinidine, Methsuximide may increase the arrhythmogenic activities of Hydroquinidine.]
[A02AD04, hydrotalcite, The risk or severity of hypotension can be increased when Hydrotalcite is combined with Methsuximide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Methsuximide.]
[A04AA03, tropisetron, Methsuximide may increase the arrhythmogenic activities of Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Methsuximide is combined with Ifenprodil.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin glargine.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation and hypotension can be increased when Telithromycin is combined with Methsuximide.]
[B01AC10, indobufen, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Methsuximide.]
[J05AB14, valganciclovir, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Valganciclovir.]
[M01AH03, valdecoxib, The risk or severity of hyperkalemia can be increased when Valdecoxib is combined with Methsuximide.]
[C01AA06, lanatoside C, The serum concentration of Lanatoside C can be increased when it is combined with Methsuximide.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Methsuximide.]
[M01AH04, parecoxib, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Methsuximide.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Bemiparin.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Emedastine.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Methsuximide.]
[M01AA06, kebuzone, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Kebuzone.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Methsuximide.]
[A02BC05, esomeprazole, The metabolism of Methsuximide can be decreased when combined with Esomeprazole.]
[C08CA09, lacidipine, Methsuximide may increase the arrhythmogenic activities of Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Methsuximide.]
[N03AX09, lamotrigine, Lamotrigine may increase the arrhythmogenic activities of Methsuximide.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Methsuximide.]
[N07BC04, lofexidine, The therapeutic efficacy of Methsuximide can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Methsuximide is combined with Lormetazepam.]
[H01AA02, cosyntropin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Methsuximide.]
[M02AA31, loxoprofen, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Loxoprofen.]
[C09AA03, lisinopril, The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Methsuximide.]
[A02AD02, magaldrate, The risk or severity of hypotension can be increased when Magaldrate is combined with Methsuximide.]
[A06AD01, magnesium carbonate, The risk or severity of hypotension can be increased when Magnesium carbonate is combined with Methsuximide.]
[C08CA11, manidipine, Methsuximide may increase the arrhythmogenic activities of Manidipine.]
[A03AA04, mebeverine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Medifoxamine.]
[C07AA14, mepindolol, The risk or severity of bradycardia can be increased when Methsuximide is combined with Mepindolol.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Methsuximide.]
[C01EB10, adenosine, Adenosine may increase the arrhythmogenic activities of Methsuximide.]
[R06AD04, methdilazine, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Methdilazine.]
[N04AA03, methixene, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, Cyclandelate may increase the arrhythmogenic activities of Methsuximide.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Methsuximide.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Methsuximide is combined with Cyclobarbital.]
[C03DA04, eplerenone, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Methsuximide.]
[N05AD03, metylperon, Methsuximide may increase the arrhythmogenic activities of Melperone.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Miglitol.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Methsuximide.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Methsuximide.]
[S01XA18, cyclosporine, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Methsuximide.]
[N06BA07, modafinil, The metabolism of Methsuximide can be decreased when combined with Modafinil.]
[R06AX02, cyproheptadine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Methsuximide.]
[M02AA02, mofebutazone, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Morniflumate.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Methsuximide.]
[M01AH05, etoricoxib, The metabolism of Methsuximide can be decreased when combined with Etoricoxib.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Methsuximide.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Methsuximide is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.]
[M01AX01, nabumetone, The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Methsuximide.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Methsuximide.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Methsuximide is combined with Nordazepam.]
[C07AB12, nebivolol, Nebivolol may increase the arrhythmogenic activities of Methsuximide.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Methsuximide is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Niaprazine.]
[C01DX16, nicorandil, Methsuximide may increase the arrhythmogenic activities of Nicorandil.]
[L02BB02, nilutamide, The metabolism of Methsuximide can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Methsuximide.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Methsuximide.]
[C01CA23, theodrenaline, Methsuximide may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC11, cisatracurium, Methsuximide may increase the neuromuscular blocking activities of Cisatracurium.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Methsuximide is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Methsuximide is combined with Escitalopram.]
[G04BD08, solifenacin, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hyperkalemia can be increased when Olsalazine is combined with Methsuximide.]
[N06AA01, desipramine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[C01AA07, deslanoside, Deslanoside may increase the arrhythmogenic activities of Methsuximide.]
[C09XA02, aliskiren, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of hyperkalemia can be increased when Oxaprozin is combined with Methsuximide.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Methsuximide.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Methsuximide is combined with Oxiracetam.]
[N04AA08, dexetimide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Methsuximide can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Methsuximide.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Methsuximide.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dextromoramide is combined with Methsuximide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine.]
[B01AC04, clopidogrel, The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Methsuximide.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Diamorphine is combined with Methsuximide.]
[C04AD01, pentifylline, Methsuximide may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Methsuximide.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Methsuximide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Methsuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Methsuximide is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Cinchocaine.]
[S01BC03, diclofenac, The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Methsuximide.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Methsuximide.]
[A03AA07, dicyclomine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[A03AX04, pinaverium, Methsuximide may increase the arrhythmogenic activities of Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Methsuximide is combined with Pipamperone.]
[A03AB14, pipenzolate, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Erlotinib.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Methsuximide.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Methsuximide.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Methsuximide.]
[A03AB11, poldine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hyperkalemia can be increased when Diflunisal is combined with Methsuximide.]
[C01AA04, digitoxin, Digitoxin may increase the arrhythmogenic activities of Methsuximide.]
[C01AA05, digoxin, Digoxin may increase the arrhythmogenic activities of Methsuximide.]
[N02CA01, dihydroergotamine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Methsuximide.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methsuximide.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Methsuximide.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Methsuximide.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Methsuximide.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Pramocaine.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Methsuximide.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methsuximide.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Methsuximide is combined with Pridinol.]
[R06AB03, dimethindene, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, The metabolism of Methsuximide can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Methsuximide.]
[N06BC02, propentofylline, Methsuximide may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Proglumetacin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Proparacaine.]
[R03DA03, proxyphylline, Methsuximide may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methsuximide.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Methsuximide.]
[C09AA06, quinapril, The risk or severity of hyperkalemia can be increased when Quinapril is combined with Methsuximide.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Methsuximide is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of hyperkalemia can be increased when Ramipril is combined with Methsuximide.]
[S01XA23, sirolimus, Methsuximide may increase the immunosuppressive activities of Sirolimus.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Methsuximide.]
[C01BA03, disopyramide, Disopyramide may increase the arrhythmogenic activities of Methsuximide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Methsuximide.]
[S02AA12, rifamycin SV, The metabolism of Methsuximide can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Methsuximide can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Methsuximide.]
[N05AX08, risperidone, The risk or severity of hypotension can be increased when Risperidone is combined with Methsuximide.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Methsuximide.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Methsuximide.]
[C03XA01, tolvaptan, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Tolvaptan.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Methsuximide.]
[S01BC05, ketorolac, The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Methsuximide.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hyperkalemia can be increased when Salsalate is combined with Methsuximide.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Methsuximide.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Domperidone.]
[N06AA16, dothiepin, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Methsuximide.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Methsuximide is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of hypotension can be increased when Sevoflurane is combined with Methsuximide.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Sibutramine.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Methsuximide.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Methsuximide.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Spirapril is combined with Methsuximide.]
[R03DA01, dyphylline, Methsuximide may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Methsuximide is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Methsuximide.]
[C07AB13, talinolol, Methsuximide may increase the arrhythmogenic activities of Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of hyperkalemia can be increased when Tenoxicam is combined with Methsuximide.]
[G04CA03, terazosin, The risk or severity of hypotension can be increased when Terazosin is combined with Methsuximide.]
[G04BD05, terodiline, Methsuximide may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Methsuximide may increase the arrhythmogenic activities of Tertatolol.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Methsuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Methsuximide is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Methsuximide is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Methsuximide is combined with Thiopropazate.]
[G04BD01, emepronium, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of hyperkalemia can be increased when Enalapril is combined with Methsuximide.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Methsuximide is combined with Tofisopam.]
[M01AG02, tolfenamic acid, Methsuximide may increase the bradycardic activities of Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Methsuximide is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Methsuximide.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Methsuximide.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Toremifene.]
[C09AA10, trandolapril, The risk or severity of hyperkalemia can be increased when Trandolapril is combined with Methsuximide.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Methsuximide is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methsuximide.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Methsuximide is combined with Triclofos.]
[A03AB08, tridihexethyl, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Methsuximide.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Triptorelin.]
[N04AA12, tropatepine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Methsuximide.]
[C02CA06, urapidil, The risk or severity of hypotension can be increased when Urapidil is combined with Methsuximide.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Methsuximide.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Methsuximide is combined with Veralipride.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Methsuximide.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Methsuximide.]
[S01GA03, xylometazoline, Methsuximide may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Methsuximide may increase the arrhythmogenic activities of Barnidipine.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Zofenopril.]
[N05CF02, zolpidem, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hyperkalemia can be increased when Zomepirac is combined with Methsuximide.]
[N03AX15, zonisamide, Zonisamide may increase the arrhythmogenic activities of Methsuximide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin glulisine.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Methsuximide is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Methsuximide.]
[C01BG01, moricizine, Moricizine may increase the arrhythmogenic activities of Methsuximide.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Methsuximide.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Methsuximide.]
[N02CA02, ergotamine, The risk or severity of hypotension can be increased when Ergotamine is combined with Methsuximide.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Valproic acid.]
[C01DA13, erythrityl tetranitrate, Methsuximide may increase the vasodilatory activities of Erythrityl tetranitrate.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Methsuximide.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Methsuximide.]
[A02BC02, pantoprazole, The metabolism of Methsuximide can be decreased when combined with Pantoprazole.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Methsuximide.]
[J04AK02, ethambutol, The metabolism of Methsuximide can be decreased when combined with Ethambutol.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methsuximide.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Methsuximide.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Methsuximide.]
[N04AA05, profenamine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, Ethosuximide may increase the arrhythmogenic activities of Methsuximide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Methsuximide.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methsuximide.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Methsuximide.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Methsuximide is combined with Sertindole.]
[C01BA05, ajmaline, Ajmaline may increase the arrhythmogenic activities of Methsuximide.]
[L04AD02, tacrolimus, Methsuximide may increase the immunosuppressive activities of Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Methsuximide.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Astemizole.]
[R06AX12, terfenadine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Methsuximide.]
[N06AB08, fluvoxamine, The metabolism of Methsuximide can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, Tocainide may increase the arrhythmogenic activities of Methsuximide.]
[C01BC08, encainide, Encainide may increase the arrhythmogenic activities of Methsuximide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Leuprolide.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Methsuximide.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Methsuximide.]
[C08CA02, felodipine, Felodipine may increase the arrhythmogenic activities of Methsuximide.]
[C08EA01, fendiline, Methsuximide may increase the arrhythmogenic activities of Fendiline.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Methsuximide.]
[M01AE04, fenoprofen, The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Methsuximide.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Methsuximide.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Methsuximide.]
[G04BD02, flavoxate, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, Flecainide may increase the arrhythmogenic activities of Methsuximide.]
[N02BG04, floctafenine, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Methsuximide.]
[N07CA03, flunarizine, Flunarizine may increase the arrhythmogenic activities of Methsuximide.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methsuximide.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Methsuximide is combined with Melitracen.]
[V03AZ01, ethanol, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Fluorouracil.]
[N06AB03, fluoxetine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Methsuximide.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Methsuximide.]
[S01BC04, flurbiprofen, The risk or severity of hyperkalemia can be increased when Flurbiprofen is combined with Methsuximide.]
[N05AG01, fluspirilene, Fluspirilene may increase the arrhythmogenic activities of Methsuximide.]
[M03AA01, alcuronium, Methsuximide may increase the neuromuscular blocking activities of Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Methsuximide.]
[J05AE10, darunavir, The serum concentration of Methsuximide can be increased when it is combined with Darunavir.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Methsuximide is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Methsuximide is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Methsuximide.]
[M03AC02, gallamine, Methsuximide may increase the neuromuscular blocking activities of Gallamine.]
[C08DA02, gallopamil, Methsuximide may increase the arrhythmogenic activities of Gallopamil.]
[S01AD09, ganciclovir, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Ganciclovir.]
[N03AA04, barbexaclone, The metabolism of Methsuximide can be increased when combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Methsuximide is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Methsuximide can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Methsuximide.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Methsuximide.]
[C01CA21, cafedrine, Methsuximide may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Liraglutide.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Methsuximide.]
[A12AA10, calcium gluceptate, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium glucoheptonate.]
[A12AA30, calcium levulinate, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium levulinate.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Pipemidic acid.]
[N07XX04, sodium oxybate, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[M01AG01, mefenamic acid, The risk or severity of hyperkalemia can be increased when Mefenamic acid is combined with Methsuximide.]
[C01DA05, pentaerythritol tetranitrate, Methsuximide may increase the vasodilatory activities of Pentaerythritol tetranitrate.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Methsuximide.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Methsuximide.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Methsuximide.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Methsuximide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Glipizide.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methsuximide.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Methsuximide.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Methsuximide.]
[C05AE01, nitroglycerin, Methsuximide may increase the vasodilatory activities of Nitroglycerin.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Methsuximide.]
[C02CA04, doxazosin, The risk or severity of hypotension can be increased when Doxazosin is combined with Methsuximide.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Methsuximide.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Methsuximide.]
[C09AA09, fosinopril, The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Methsuximide.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Methsuximide.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Histrelin.]
[N05AH04, quetiapine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin aspart.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Methsuximide is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Methsuximide is combined with Allobarbital.]
[C09CA01, losartan, Losartan may increase the arrhythmogenic activities of Methsuximide.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Heparin is combined with Methsuximide.]
[B05CB03, magnesium citrate, The risk or severity of hypotension can be increased when Magnesium citrate is combined with Methsuximide.]
[A12CC03, magnesium gluconate, The risk or severity of hypotension can be increased when Magnesium gluconate is combined with Methsuximide.]
[A07EC02, mesalamine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Methsuximide.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Methsuximide.]
[N05CA16, hexobarbital, The metabolism of Methsuximide can be increased when combined with Hexobarbital.]
[C08CA10, nilvadipine, Methsuximide may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may increase the arrhythmogenic activities of Methsuximide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Oxatomide.]
[C09AA04, perindopril, The risk or severity of hyperkalemia can be increased when Perindopril is combined with Methsuximide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Methsuximide.]
[R05DA03, hydrocodone, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Methsuximide.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Methsuximide.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Methsuximide.]
[G04BD06, propiverine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Methsuximide is combined with Prothipendyl.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Methsuximide can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Methsuximide.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Methsuximide.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Methsuximide.]
[N06AA02, imipramine, The metabolism of Methsuximide can be decreased when combined with Imipramine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Terlipressin.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Methsuximide.]
[L01CE01, topotecan, Methsuximide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Methsuximide.]
[S01BC01, indomethacin, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Methsuximide.]
[C02CA02, indoramin, The risk or severity of hypotension can be increased when Indoramin is combined with Methsuximide.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Methsuximide is combined with Milnacipran.]
[A03AA30, piperidolate, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Articaine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Sitagliptin.]
[V08AB02, iohexol, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Iohexol.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Methsuximide.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Methsuximide.]
[R06AE01, buclizine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Vildagliptin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Anagrelide.]
[C07AA01, alprenolol, Alprenolol may increase the arrhythmogenic activities of Methsuximide.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Methsuximide is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Iproniazid is combined with Methsuximide.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methsuximide.]
[C09AA16, imidapril, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Methsuximide.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Methsuximide.]
[J04AC01, isoniazid, The metabolism of Methsuximide can be decreased when combined with Isoniazid.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Exenatide.]
[C05AE02, isosorbide dinitrate, Methsuximide may increase the vasodilatory activities of Isosorbide dinitrate.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Methsuximide.]
[L04AC07, tocilizumab, The metabolism of Methsuximide can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Methsuximide.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Methsuximide is combined with Ketanserin.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Methsuximide.]
[N05AH03, olanzapine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hyperkalemia can be increased when Ketoprofen is combined with Methsuximide.]
[L04AA24, abatacept, The metabolism of Methsuximide can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Mizolastine.]
[N04BC09, rotigotine, Methsuximide may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Nalidixic acid.]
[C07AG01, labetalol, The risk or severity of bradycardia can be increased when Methsuximide is combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Methsuximide.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Methsuximide.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Methsuximide.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Lacosamide.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Methsuximide.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Levodopa is combined with Methsuximide.]
[S02DA01, lidocaine, Lidocaine may increase the arrhythmogenic activities of Methsuximide.]
[C08EX01, lidoflazine, Methsuximide may increase the arrhythmogenic activities of Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Methsuximide can be decreased when combined with Armodafinil.]
[C03DB01, amiloride, The risk or severity of hyperkalemia can be increased when Amiloride is combined with Methsuximide.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Methsuximide.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Lofepramine.]
[A07DA03, loperamide, Loperamide may increase the arrhythmogenic activities of Methsuximide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Methsuximide.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Methsuximide.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Methsuximide.]
[B05XA11, magnesium chloride, The risk or severity of hypotension can be increased when Magnesium chloride is combined with Methsuximide.]
[G04BX01, magnesium hydroxide, The risk or severity of hypotension can be increased when Magnesium hydroxide is combined with Methsuximide.]
[A12CC10, magnesium oxide, The risk or severity of hypotension can be increased when Magnesium oxide is combined with Methsuximide.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Methsuximide can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Methsuximide.]
[N06AA21, maprotiline, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Methsuximide.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Methsuximide.]
[M02AA18, meclofenamic acid, The risk or severity of hyperkalemia can be increased when Meclofenamic acid is combined with Methsuximide.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Methsuximide is combined with Medazepam.]
[C01AA08, medigoxin, Methsuximide may increase the arrhythmogenic activities of Metildigoxin.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Methsuximide.]
[P01BC02, mefloquine, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Methsuximide.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Dalteparin.]
[N05CH01, melatonin, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Melatonin.]
[N06DX01, memantine, The metabolism of Methsuximide can be decreased when combined with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Methsuximide.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Methsuximide.]
[N03AA01, mephobarbital, The metabolism of Methsuximide can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Methsuximide.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Methsuximide is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Methsuximide.]
[N05AX13, paliperidone, The risk or severity of hypotension can be increased when Paliperidone is combined with Methsuximide.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Metformin.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Methsuximide.]
[H01CB03, lanreotide, Methsuximide may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Methsuximide.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Metamfetamine is combined with Methsuximide.]
[A03AB07, methantheline, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Methsuximide.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Methsuximide.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Methsuximide.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Methsuximide is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Methsuximide can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Methsuximide.]
[N05CA15, methohexital, The metabolism of Methsuximide can be increased when combined with Methohexital.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Methsuximide is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methsuximide.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Methsuximide.]
[C02AB01, methyldopa, Methyldopa may increase the bradycardic activities of Methsuximide.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Methsuximide is combined with Methylene blue.]
[R03DA05, aminophylline, Methsuximide may increase the excretion rate of Aminophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA04, methylphenidate, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Methsuximide.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Methsuximide.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Methsuximide.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Methsuximide.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Methsuximide.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Methsuximide.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Methsuximide.]
[N06AX03, mianserin, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Mianserin.]
[S02AA13, miconazole, The metabolism of Methsuximide can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hyperkalemia can be increased when Aminophenazone is combined with Methsuximide.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Parnaparin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Methsuximide.]
[C01CA17, midodrine, Midodrine may increase the bradycardic activities of Methsuximide.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Methsuximide.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Tinzaparin.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Methsuximide.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Valsartan is combined with Methsuximide.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Methsuximide.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Amiodarone is combined with Methsuximide.]
[N06AA09, amitriptyline, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Methsuximide.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Methsuximide.]
[L04AB05, certolizumab pegol, The metabolism of Methsuximide can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Ammonium chloride.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Pazopanib.]
[M03AC03, vecuronium, Methsuximide may increase the neuromuscular blocking activities of Vecuronium.]
[N05CA02, amobarbital, The metabolism of Methsuximide can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Methsuximide.]
[G04CA04, silodosin, The risk or severity of hypotension can be increased when Silodosin is combined with Methsuximide.]
[N06AA17, amoxapine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The serum concentration of Fosphenytoin can be increased when it is combined with Methsuximide.]
[C07AA12, nadolol, Nadolol may increase the arrhythmogenic activities of Methsuximide.]
[N04BC04, ropinirole, Methsuximide may increase the sedative activities of Ropinirole.]
[J01CF06, nafcillin, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Methsuximide is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Methsuximide.]
[L04AC03, anakinra, The metabolism of Methsuximide can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, The risk or severity of hyperkalemia can be increased when Naproxen is combined with Methsuximide.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Methsuximide.]
[L02BG04, letrozole, The metabolism of Methsuximide can be decreased when combined with Letrozole.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Methsuximide.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Repaglinide.]
[C01CX08, levosimendan, Levosimendan may increase the arrhythmogenic activities of Methsuximide.]
[N05AX14, iloperidone, The risk or severity of hypotension can be increased when Iloperidone is combined with Methsuximide.]
[J02AA01, amphotericin B, Methsuximide may decrease the nephrotoxic activities of Amphotericin B.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The metabolism of Methsuximide can be decreased when combined with Telmisartan.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Nialamide is combined with Methsuximide.]
[C08CA04, nicardipine, Nicardipine may increase the arrhythmogenic activities of Methsuximide.]
[C04AE02, nicergoline, The risk or severity of hypotension can be increased when Nicergoline is combined with Methsuximide.]
[C08CA05, nifedipine, Nifedipine may increase the arrhythmogenic activities of Methsuximide.]
[M02AA17, niflumic acid, The risk or severity of hyperkalemia can be increased when Niflumic acid is combined with Methsuximide.]
[V03AB22, amyl nitrite, Methsuximide may increase the vasodilatory activities of Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Methsuximide.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Methsuximide.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Methsuximide.]
[C08CA08, nitrendipine, Nitrendipine may increase the arrhythmogenic activities of Methsuximide.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Methsuximide.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Methsuximide.]
[N04BC05, pramipexole, Methsuximide may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Methsuximide may increase the hypotensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Methsuximide.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Methsuximide.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Methsuximide.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Methsuximide.]
[N06AA10, nortriptyline, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[G02CA02, nylidrin, Methsuximide may increase the arrhythmogenic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Methsuximide.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Methsuximide can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Methsuximide can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Methsuximide is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Methsuximide is combined with Opium.]
[G04CA02, tamsulosin, The risk or severity of hypotension can be increased when Tamsulosin is combined with Methsuximide.]
[C01AC01, ouabain, The serum concentration of Ouabain can be increased when it is combined with Methsuximide.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Methsuximide.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Oxolinic acid.]
[C07AA02, oxprenolol, Oxprenolol may increase the arrhythmogenic activities of Methsuximide.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Methsuximide.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Methsuximide.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hyperkalemia can be increased when Oxyphenbutazone is combined with Methsuximide.]
[A03AB03, oxyphenonium, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methsuximide.]
[N05AH05, asenapine, The risk or severity of hypotension can be increased when Asenapine is combined with Methsuximide.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Danaparoid.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.]
[M03AC01, pancuronium, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Methsuximide.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Papaverine.]
[N05CC05, paraldehyde, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Pargyline is combined with Methsuximide.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Methsuximide.]
[G04BD11, fesoterodine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of bradycardia can be increased when Methsuximide is combined with Penbutolol.]
[N05AG03, penfluridol, Methsuximide may increase the arrhythmogenic activities of Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Methsuximide.]
[N05CA01, pentobarbital, The metabolism of Methsuximide can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, Methsuximide may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Methsuximide.]
[C08EX02, perhexiline, Perhexiline may increase the arrhythmogenic activities of Methsuximide.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Methsuximide.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Methsuximide.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Phenformin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Methsuximide.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be decreased when combined with Methsuximide.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Methsuximide.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Methsuximide.]
[V03AB36, phentolamine, The risk or severity of hypotension can be increased when Phentolamine is combined with Methsuximide.]
[M02AA01, phenylbutazone, The risk or severity of hyperkalemia can be increased when Phenylbutazone is combined with Methsuximide.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be decreased when Methsuximide is combined with Phenylephrine.]
[A02BC06, dexlansoprazole, The metabolism of Methsuximide can be decreased when combined with Dexlansoprazole.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be increased when it is combined with Methsuximide.]
[L04AB06, golimumab, The metabolism of Methsuximide can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Levofloxacin.]
[C08CX01, mibefradil, Mibefradil may increase the arrhythmogenic activities of Methsuximide.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of bradycardia can be increased when Methsuximide is combined with Pindolol.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Methsuximide.]
[C09CA02, eprosartan, The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Methsuximide.]
[A02BX03, pirenzepine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hyperkalemia can be increased when Piroxicam is combined with Methsuximide.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Grepafloxacin.]
[N02CX01, pizotyline, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Methsuximide can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Methsuximide.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Methsuximide is combined with Proxibarbal.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Rosiglitazone.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methsuximide.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Methsuximide.]
[L04AC08, canakinumab, The metabolism of Methsuximide can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Methsuximide.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Methsuximide.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Methsuximide.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin lispro.]
[C07AB01, practolol, Practolol may increase the arrhythmogenic activities of Methsuximide.]
[C01BA08, prajmaline, Methsuximide may increase the arrhythmogenic activities of Prajmaline.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Methsuximide.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Methsuximide.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Methsuximide.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Antazoline.]
[C01DX02, prenylamine, Prenylamine may increase the arrhythmogenic activities of Methsuximide.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Primaquine.]
[N03AA03, primidone, The metabolism of Methsuximide can be increased when combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Probucol.]
[C01BA02, procainamide, Procainamide may increase the arrhythmogenic activities of Methsuximide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Methsuximide.]
[C10AB05, fenofibrate, The metabolism of Methsuximide can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methsuximide.]
[N04AA04, procyclidine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Methsuximide.]
[N05AA03, promazine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, Propafenone may increase the arrhythmogenic activities of Methsuximide.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Methsuximide is combined with Propanidid.]
[A03AB05, propantheline, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of hypotension can be increased when Periciazine is combined with Methsuximide.]
[N05CM06, propiomazine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Methsuximide.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methsuximide.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Methsuximide.]
[C01AB01, proscillaridin, The serum concentration of Proscillaridin can be increased when it is combined with Methsuximide.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Methsuximide.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Methsuximide.]
[N05AX12, aripiprazole, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Methsuximide.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Methsuximide is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Methsuximide is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Methsuximide is combined with Pyrantel.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Methsuximide.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Methsuximide is combined with Mepyramine.]
[C01BA01, quinidine, Quinidine may increase the arrhythmogenic activities of Methsuximide.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Quinine.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Methsuximide.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Methsuximide.]
[J04AB02, rifampin, The metabolism of Methsuximide can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Methsuximide.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hyperkalemia can be increased when Sulfasalazine is combined with Methsuximide.]
[S01BC08, salicylic acid, The risk or severity of hyperkalemia can be increased when Salicylic acid is combined with Methsuximide.]
[S01FA02, scopolamine, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The metabolism of Methsuximide can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Methsuximide.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Methsuximide.]
[C07AA07, sotalol, Sotalol may increase the arrhythmogenic activities of Methsuximide.]
[C03DA01, spironolactone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Methsuximide.]
[C01DA14, isosorbide mononitrate, Methsuximide may increase the vasodilatory activities of Isosorbide mononitrate.]
[H02CA04, levoketoconazole, The therapeutic efficacy of Levoketoconazole can be increased when used in combination with Methsuximide.]
[M01AE11, tiaprofenic acid, The risk or severity of hyperkalemia can be increased when Tiaprofenic acid is combined with Methsuximide.]
[D11AX02, gamma-linolenic acid, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Gamolenic acid.]
[A12AA11, calcium pangamate, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium pangamate.]
[R03BB01, ipratropium bromide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
